Perceptive Advisors LLC Makes New Investment in Palisade Bio, Inc. $PALI

Perceptive Advisors LLC purchased a new position in Palisade Bio, Inc. (NASDAQ:PALI) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,050,000 shares of the company’s stock, valued at approximately $28,318,000. Perceptive Advisors LLC owned approximately 8.09% of Palisade Bio as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BIT Capital GmbH purchased a new stake in Palisade Bio in the fourth quarter worth about $717,000. B Group Inc. purchased a new stake in Palisade Bio in the fourth quarter worth about $10,575,000. Persistent Asset Partners Ltd purchased a new stake in Palisade Bio in the fourth quarter worth about $978,000. Artia Global Partners LP purchased a new stake in Palisade Bio in the fourth quarter worth about $4,682,000. Finally, Platinum Investment Management Ltd. purchased a new stake in Palisade Bio in the fourth quarter worth about $1,561,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. HC Wainwright assumed coverage on Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target for the company. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Stifel Nicolaus initiated coverage on Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price for the company. Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price for the company. Finally, Weiss Ratings cut Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.20.

Palisade Bio Trading Down 1.1%

NASDAQ:PALI opened at $1.76 on Thursday. Palisade Bio, Inc. has a 12-month low of $0.53 and a 12-month high of $2.86. The stock has a 50-day moving average price of $1.97 and a 200 day moving average price of $1.90. The stock has a market capitalization of $305.50 million, a P/E ratio of -1.74 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, research analysts predict that Palisade Bio, Inc. will post -0.21 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.